Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T, Ueda A, Ogawa K, Motoo I, Kajiura S, Nakajima T, Hirano K, Okumura T, Tsukada K, Hara T, Suzuki N, Nakada N, Horikawa N, Fujii T, Yasuda I. Ando T, et al. Among authors: nakada n. In Vivo. 2021 Jan-Feb;35(1):475-482. doi: 10.21873/invivo.12281. In Vivo. 2021. PMID: 33402499 Free PMC article.
Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer.
Ando T, Hosokawa A, Sakumura M, Motoo I, Kajiura S, Hirano K, Miwa T, Yokota T, Nakada N, Ueda Y, Ueda A, Tsukada K, Ogawa K, Nakaya A, Teramoto A, Nanjo S, Mihara H, Fujinami H, Fujii T, Yasuda I. Ando T, et al. Among authors: nakada n. Oncology. 2023;101(1):59-68. doi: 10.1159/000526577. Epub 2022 Sep 14. Oncology. 2023. PMID: 36103845
CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer.
Ueda A, Yuki S, Ando T, Hosokawa A, Nakada N, Kito Y, Motoo I, Ito K, Sakumura M, Nakayama Y, Ueda Y, Kajiura S, Nakashima K, Harada K, Kawamoto Y, Komatsu Y, Yasuda I. Ueda A, et al. Among authors: nakada n. Cancers (Basel). 2024 Feb 22;16(5):871. doi: 10.3390/cancers16050871. Cancers (Basel). 2024. PMID: 38473233 Free PMC article.
Human Vγ9Vδ2 T cells exhibit antifungal activity against Aspergillus fumigatus and other filamentous fungi.
Koga S, Takazono T, Namie H, Okuno D, Ito Y, Nakada N, Hirayama T, Takeda K, Ide S, Iwanaga N, Tashiro M, Sakamoto N, Watanabe A, Izumikawa K, Yanagihara K, Tanaka Y, Mukae H. Koga S, et al. Among authors: nakada n. Microbiol Spectr. 2024 Apr 2;12(4):e0361423. doi: 10.1128/spectrum.03614-23. Epub 2024 Mar 1. Microbiol Spectr. 2024. PMID: 38426765 Free PMC article.
Risk factor of non-tuberculous Mycobacterium infection in patients with rheumatoid arthritis and other autoimmune diseases receiving biologic agents: A multicenter retrospective study.
Ashizawa H, Takazono T, Kawashiri SY, Nakada N, Ito Y, Ashizawa N, Hirayama T, Yoshida M, Takeda K, Iwanaga N, Takemoto S, Ide S, Mihara T, Tomari S, Sakamoto N, Obase Y, Izumikawa K, Yanagihara K, Kawakami A, Mukae H. Ashizawa H, et al. Among authors: nakada n. Respir Investig. 2024 May;62(3):322-327. doi: 10.1016/j.resinv.2024.02.005. Epub 2024 Feb 23. Respir Investig. 2024. PMID: 38401245
Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial.
Takazono T, Hosogaya N, Fukushima K, Morio R, Irifune S, Miyamura T, Harada Y, Nagayoshi Y, Kondo A, Mihara T, Fukuda Y, Sasaki E, Sawai T, Imamura Y, Morikawa T, Futsuki Y, Inoue Y, Fukushima K, Suyama N, Tanaka H, Hanaka T, Shimabukuro I, Hata R, Ota K, Morimoto S, Nakada N, Ito Y, Yoshida M, Takeda K, Ide S, Iwanaga N, Nemoto K, Funada M, Izumikawa K, Yatera K, Yanagihara K, Mukae H. Takazono T, et al. Among authors: nakada n. J Infect Chemother. 2024 Jul;30(7):597-602. doi: 10.1016/j.jiac.2024.01.003. Epub 2024 Jan 6. J Infect Chemother. 2024. PMID: 38190963 Free article. Clinical Trial.
160 results